-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rucaparib Camsylate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rucaparib Camsylate in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rucaparib Camsylate in Solid Tumor Drug Details: Rucaparib camsylate (Rubraca) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ribociclib Succinate in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ribociclib Succinate in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ribociclib Succinate in Recurrent Glioblastoma Multiforme (GBM) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GB-2064 in Myelofibrosis Drug Details: GB-2064 (PAT-1251) Is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details: GB-2064 (PAT-1251)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:...
-
Product Insights
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drugs In Development, 2023’, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) - Drugs In Development, 2023’, provides an overview of the Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Myelofibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myelofibrosis - Drugs In Development, 2023’, provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Liver Cirrhosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Cirrhosis - Drugs In Development, 2023’, provides an overview of the Liver Cirrhosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...